Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diversity of US participants in AstraZeneca-sponsored clinical trials.
Cabrera C, Fernández-Llaneza D, Ghazoui Z, D'Abrantes S, Esparza-Franco MA, Sopp C, Maj B, Chiou VL, Valastro B, Pangalos MN, Galbraith S, Ghiorghiu S, Massacesi C. Cabrera C, et al. Among authors: massacesi c. Contemp Clin Trials. 2024 May;140:107496. doi: 10.1016/j.cct.2024.107496. Epub 2024 Mar 11. Contemp Clin Trials. 2024. PMID: 38467274 Free article.
Cardiac resynchronization therapy with multipoint pacing via quadripolar lead versus traditional biventricular pacing: A systematic review and meta-analysis of clinical studies on hemodynamic, clinical, and prognostic parameters.
Massacesi C, Ceriello L, Maturo F, Porreca A, Appignani M, Di Girolamo E. Massacesi C, et al. Heart Rhythm O2. 2021 Dec 17;2(6Part B):682-690. doi: 10.1016/j.hroo.2021.09.012. eCollection 2021 Dec. Heart Rhythm O2. 2021. PMID: 34988517 Free PMC article.
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Melillo G, Chand V, Yovine A, Gupta A, Massacesi C. Melillo G, et al. Among authors: massacesi c. Adv Ther. 2021 Jun;38(6):2759-2778. doi: 10.1007/s12325-021-01675-0. Epub 2021 Apr 21. Adv Ther. 2021. PMID: 33881745 Free PMC article. Review.
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Marabelle A, et al. Among authors: massacesi c. Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. Ann Oncol. 2018. PMID: 30295695 Free PMC article.
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Pistilli B, et al. Among authors: massacesi c. Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2. Breast Cancer Res Treat. 2018. PMID: 29198055 Free PMC article. Clinical Trial.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Shaw AT, et al. Among authors: massacesi c. Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.
52 results